CS
FBRX icon

Candriam SCA’s Forte Biosciences FBRX Stock Holding History

Candriam SCA’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.2M Buy
+84,803
New +$2.44M 0.01% 508

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Candriam SCA's FBRX Position: Q1 2026 in Review

Candriam SCA opened a new position in Forte Biosciences (FBRX) in Q1 2026: 84,803 shares worth $2.2M. The stake represents 0.01% of the portfolio and ranks #508 among its holdings.

68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Candriam SCA held 84,803 shares of Forte Biosciences worth $2.2M as of Q1 2026.
  • Forte Biosciences was a new Candriam SCA position in Q1 2026.
  • Forte Biosciences made up 0.01% of Candriam SCA's portfolio in Q1 2026, its #508 holding.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.